Triplet rechallenge of BEACON regimen for RAS wild-type and BRAF V600E mutant metastatic colorectal cancer

ABSTRACT: Interventions: Encorafenib 300 mg once daily Binimetinib 45 mg twice daily Cetuximab 400 mg/m^2 Day 1, 250 mg/m^2 Day 8, 15, 22 (250 mg/m^2 from Cycle 2 later) These treatments are repeated every 28 days in one cycle. Primary outcome(s): Objective Response Rate (ORR) as determined by the site-investigator Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

DISEASE(S): Unresectable, Advanced Or Recurrent Colorectal Cancer With Ras Wild-type And Braf V600e Mutation

PROVIDER: 2614542 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR